Overview

Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept

Status:
Completed

Trial end date:
2014-03-04

Target enrollment:
0

Participant gender:
All

Summary

The study will estimate the preference of rheumatoid arthritis (RA) and Plaque Psoriasis (PsO) patients who self inject etanercept for one of two experimental autoinjectors.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Amgen

Treatments:

Etanercept

Criteria

Inclusion Criteria: Diagnosis of moderate to severe Rheumatoid Arthritis (RA) or moderate
to severe Plaque Psoriasis (PsO) and a candidate for treatment with etanercept in the
opinion of the investigator in addition to the caring physician's intent to initiate
treatment with etanercept. - Naive to etanercept. - Naive to other autoinjector pens or
prefilled syringes for Tumor Necrosis Factor (TNF)-inhibitor therapy or other subcutaneous
biologics for RA. - Willing to self-inject per investigator judgement at screening and
capable of self-injection using the autoinjector A or B as documented at baseline by the
investigator. - Able to read and write in English. -

Exclusion Criteria: Latex allergy. - Subject has an active infection (including chronic or
localized infections) for which anti-infectives were indicated within 4 weeks prior to
first dose of etanercept. - Subject had prosthetic joint infection within 5 years of
screening or native joint infection within 1 year of screening.

- Other criteria may apply.